Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Sugihara · SciRah

Researcher profile · Semantic Scholar

M. Sugihara

Share profile

M. Sugihara — researcher profile on SciRah

h-index: 23
Works: 69
Citations: 3,523

Most-cited papers

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
K. Shitara, Y. Bang, S. Iwasa, N. Sugimoto +12 more
2020New England Journal of Medicine1,047 citations Open access
Semantic Scholar
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
S. Modi, Haeseong Park, R. Murthy, H. Iwata +13 more
2020Journal of Clinical Oncology577 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
K. Tamura, J. Tsurutani, S. Takahashi, H. Iwata +13 more
2019The Lancet Oncology297 citations
Semantic Scholar
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
J. Tsurutani, H. Iwata, I. Krop, P. Jänne +12 more
2020Cancer Discovery292 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
K. Shitara, H. Iwata, S. Takahashi, K. Tamura +11 more
2019The Lancet Oncology185 citations
Semantic Scholar
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
K. Shitara, Yung-Jue Bang, S. Iwasa, N. Sugimoto +17 more
2024Nature Medicine112 citations Open access
Semantic Scholar
Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
K. Yamaguchi, Y. Bang, S. Iwasa, N. Sugimoto +14 more
2022Journal of Clinical Oncology110 citations Open access
Semantic Scholar
Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients
J. Kato, Norimitsu Matsui, Yoshihiro Kakehi, Emiko Murayama +2 more
2019Pain93 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
H. Iwata, K. Tamura, T. Doi, J. Tsurutani +14 more
201892 citations
Semantic Scholar
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
Jih-hsiang Lee, T. Chen, Chih-Hung Hsu, Y. Yen +9 more
2019Investigational new drugs59 citations Open access
Semantic Scholar
Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score
M. Sugihara
2010Pharmaceutical statistics59 citations
Semantic Scholar
Analysis of the Serum Bile Acid Composition for Differential Diagnosis in Patients with Liver Disease
Tomonori Sugita, K. Amano, Masanori Nakano, N. Masubuchi +2 more
2015Gastroenterology Research and Practice53 citations Open access
Semantic Scholar
Pravastatin use and cancer risk: a meta‐analysis of individual patient data from long‐term prospective controlled trials in Japan
Y. Matsushita, M. Sugihara, Junpei Kaburagi, Masumi Ozawa +4 more
2010Pharmacoepidemiology and Drug Safety48 citations
Semantic Scholar
1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
K. Yamaguchi, Y. Bang, S. Iwasa, N. Sugimoto +12 more
202046 citations Open access
Semantic Scholar
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients
W. Ichikawa, Keisuke Uehara, K. Minamimura, C. Tanaka +16 more
2015British Journal of Cancer35 citations Open access
Semantic Scholar
Oxidative stress markers, secondary bile acids and sulfated bile acids classify the clinical liver injury type: Promising diagnostic biomarkers for cholestasis.
N. Masubuchi, M. Sugihara, Tomonori Sugita, K. Amano +2 more
2016Chemico-Biological Interactions32 citations
Semantic Scholar
OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer
J. Tsurutani, Haeseong Park, T. Doi, S. Modi +11 more
2018Journal of Thoracic Oncology29 citations Open access
Semantic Scholar
A Phase II Multi-Center Study of Triple Therapy with Paclitaxel, S-1 and Cisplatin in Patients with Advanced Gastric Cancer
H. Iwase, Masaaki Shimada, T. Tsuzuki, K. Ina +5 more
2011Oncology29 citations
Semantic Scholar
Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
T. Yamashita, J. Sohn, E. Tokunaga, N. Niikura +14 more
2024Breast Cancer28 citations Open access
Semantic Scholar
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer
H. Iwata, Bing-He Xu, Sung-Bae Kim, Wei-Pang Chung +16 more
2024Cancer Science28 citations Open access
Semantic Scholar
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies
S. Takahashi, H. Bando, Ichiro Kinoshita, S. Modi +8 more
2024Japanese Journal of Clinical Oncology26 citations Open access
Semantic Scholar
A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer.
H. Iwase, M. Shimada, T. Tsuzuki, Y. Horiuchi +7 more
2005Anticancer Research26 citations
Semantic Scholar
Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment
Manabu Kato, N. Tajima, Takako Shimizu, M. Sugihara +3 more
2017Journal of clinical pharmacology23 citations Open access
Semantic Scholar
Abstract P6-17-02: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study
S. Modi, J. Tsurutani, K. Tamura, Haeseong Park +12 more
2019Poster Session Abstracts21 citations
Semantic Scholar
Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.
T. Kogawa, K. Yonemori, N. Masuda, S. Takahashi +16 more
201819 citations
Semantic Scholar
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
K. Yamaguchi, Y. Bang, S. Iwasa, N. Sugimoto +12 more
202117 citations
Semantic Scholar
Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.
H. Bando, I. Kinoshita, S. Modi, J. Tsurutani +8 more
2021Journal of Clinical Oncology17 citations
Semantic Scholar
Impact of UGT1A1 genotype upon toxicities of combination with low‐dose irinotecan plus platinum
M. Takano, Kaichiro Yamamoto, T. Tabata, Y. Minegishi +12 more
2016Asia-Pacific Journal of Clinical Oncology13 citations Open access
Semantic Scholar
Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study
H. Yasui, A. Takeno, H. Hara, H. Imamura +15 more
2022International Journal of Colorectal Disease11 citations Open access
Semantic Scholar
O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
K. Shitara, Y. Bang, S. Iwasa, N. Sugimoto +15 more
2021Annals of Oncology11 citations Open access
Semantic Scholar
The relationship between low-density lipoprotein cholesterol levels and the incidence of cardiovascular disease in high-risk patients treated with pravastatin: main results of the APPROACH-J study.
H. Daida, T. Teramoto, Yasuhisa Kitagawa, Y. Matsushita +1 more
2014International Heart Journal11 citations Open access
Semantic Scholar
Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer.
T. Yoshino, H. Iwata, K. Tamura, Shin-ichiro Takahashi +13 more
2018Annals of Oncology8 citations Open access
Semantic Scholar
Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer.
S. Iwasa, K. Shitara, S. Takahashi, Haeseong Park +12 more
20186 citations
Semantic Scholar
Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer.
T. Kogawa, K. Yonemori, Y. Naito, E. Noguchi +10 more
20176 citations
Semantic Scholar
Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
K. Shitara, K. Yamaguchi, K. Muro, H. Yasui +9 more
2023International Journal of Clinical Oncology5 citations Open access
Semantic Scholar
PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03
S. Im, Bing-He Xu, Sung-Bae Kim, Wei-Pang Chung +16 more
2022Annals of Oncology5 citations Open access
Semantic Scholar
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.
D. Cella, M. Hackshaw, G. Vondeling, L. Bennett +6 more
2021Journal of Clinical Oncology5 citations
Semantic Scholar
Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses
Kazuo Tamura, S. Modi, J. Tsurutani, S. Takahashi +10 more
2019Poster Session Abstracts5 citations
Semantic Scholar
A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.
J. Baselga, K. Tamura, T. Yamashita, S. Modi +8 more
20185 citations
Semantic Scholar
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
K. Yamaguchi, Y. Bang, S. Iwasa, N. Sugimoto +12 more
2022Journal of Clinical Oncology4 citations Open access
Semantic Scholar
O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
K. Yamaguchi, Y. Bang, S. Iwasa, N. Sugimoto +12 more
20204 citations Open access
Semantic Scholar
Estimating Antihypertensive Effects of Combination Therapy in an Observational Study Using Marginal Structural Models
M. Sugihara, T. Kushiro, I. Saito, Y. Matsushita +1 more
2009Biometrical journal. Biometrische Zeitschrift4 citations
Semantic Scholar
[Pharmacological and clinical study results of trastuzumab deruxtecan (T-DXd, ENHERTU®)].
K. Saito, Reina Kaneko, T. Kamio, Emi Kamiyama +2 more
2021Nihon yakurigaku zasshi. Folia pharmacologica Japonica3 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
K. Shitara, Y. Bang, S. Iwasa, N. Sugimoto +12 more
20203 citations
Semantic Scholar
A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
K. Shitara, Y. Bang, H. Chung, H. Yabusaki +16 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar
A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
K. Yamaguchi, Y. Bang, D. Sakai, H. Yasui +5 more
20183 citations
Semantic Scholar
286P Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
S. Modi, B. Glass, A. Prakash, Amaro Taylor-Weiner +11 more
20202 citations Open access
Semantic Scholar
Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer
S. Takahashi, S. Modi, J. Tsurutani, I. Krop +11 more
2019Annals of Oncology2 citations Open access
Semantic Scholar
Integration of Drug Use-Results Survey (DUS) Data of a Pharmaceutical Manufacturer
Y. Matsushita, M. Sugihara, K. Kawasugi
20102 citations Open access
Semantic Scholar
Multicenter phase II study of triple combination with S-1 and cisplatin (CDDP) plus paclitaxel (TXL) in patients with advanced gastric cancer
H. Iwase, T. Tsuzuki, M. Shimada, K. Ina +6 more
20082 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Saito×17
Invite
K. Saito — researcher profile on SciRah
K. Yamaguchi×16
Invite
K. Yamaguchi — researcher profile on SciRah
K. Shitara×15
Invite
K. Shitara — researcher profile on SciRah
S. Modi×15
Invite
S. Modi — researcher profile on SciRah

×13

Invite

H. Iwata — researcher profile on SciRah

Invite

Y. Bang — researcher profile on SciRah

Invite

S. Iwasa — researcher profile on SciRah

Invite

D. Sakai — researcher profile on SciRah

J. Tsurutani×12

Invite

J. Tsurutani — researcher profile on SciRah

N. Sugimoto×10

Invite

N. Sugimoto — researcher profile on SciRah

H. Kawakami×10

Invite

H. Kawakami — researcher profile on SciRah

H. Yabusaki×10

Invite

H. Yabusaki — researcher profile on SciRah